Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

ClinicalTrials.gov ID: NCT02291419

Public ClinicalTrials.gov record NCT02291419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this pilot study is to establish the rate of cardiovascular events in patients with elevated troponins levels after major, non-cardiac surgery and to evaluate the efficacy and safety of FDA approved study drug (ticagrelor) compared to aspirin in these patients. Data from current studies suggest that myocardial injury detected by minor elevations in troponin levels within 3 days after non-cardiac surgery may occur in 10-24% of patients and is associated with an increased risk of mortality at 30 days and 1 year. There are no current guidelines for care of patients with elevated troponin levels in the absence of acute coronary syndrome. This study will assess if the increased risk of these patients is modifiable by an anti-platelet medication and evaluate the safety of this medication. Patients will be randomized in an open label fashion to receive ticagrelor (anti-platelet medication) or 81 mg. aspirin. Patients will be followed on study treatment for 12 months, with the last contact at one month post treatment discontinuation.

Study identification

NCT ID
NCT02291419
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
The Cleveland Clinic
Other
Enrollment
6 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2015
Primary completion
May 31, 2016
Completion
May 31, 2016
Last update posted
Feb 8, 2017

2015 – 2016

United States locations

U.S. sites
24
U.S. states
15
U.S. cities
22
Facility City State ZIP Site status
University of South Alabama Health System Mobile Alabama 36617
Arkansas Site Management Service, LLC Little Rock Arkansas 72211
University of Florida College of Medicine - Jacksonville Jacksonville Florida 32209
Florida Hospital Orthopaedic Institute and Fracture Care Center Orlando Florida 32804
University of South Florida Tampa Florida 33060
Central Georgia Heart Center Macon Georgia 31201
Saint Vincent Medical Group Indianapolis Indiana 46260
University of Kentucky Lexington Kentucky 40536
Sinai Hospital of Baltimore Baltimore Maryland 21215
McLaren Bay Region Bay City Michigan 48708
Henry Ford Hospital Detroit Michigan 48202
McLaren Macomb Mount Clemens Michigan 48043
University of Minnesota Minneapolis Minnesota 55455
New York University School of Medicine New York New York 10016
Cincinnati VA Medical Center Cincinnati Ohio 45220
VA Medical Center - Cleveland Louis Stokes Cleveland Ohio 44106
MetroHealth Medical Center Cleveland Ohio 44109
Cleveland Clinic Cleveland Ohio 44195
Miami Valley Hospital Dayton Ohio 45409
Oklahoma Heart Institute Tulsa Oklahoma 74104
Oregon Health and Science University Portland Oregon 97239
VA North Texas Health Care System Dallas Texas 75216
University of Texas Health Science Center at Houston Houston Texas 77030
Overlake Hospital Medical Center Bellevue Washington 98004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02291419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 8, 2017 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02291419 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →